Scientists have identified a compound, TLC-2716, that reduces “remnant” cholesterol by up to 61 percent in a recent clinical trial, offering a potential new approach to managing cardiovascular risk. The findings, released this week, indicate the oral medication was safe and well-tolerated by participants.
Remnant cholesterol, a type of cholesterol-rich particle, has emerged as an independent risk factor for heart disease, even in individuals with optimal levels of LDL cholesterol. Researchers reported that TLC-2716 produced “substantial improvements in plasma lipid metabolism,” and its oral administration could offer advantages in terms of patient convenience and cost, potentially allowing for combination therapies.
The discovery of TLC-2716 coincides with other significant scientific advancements announced this week. A NASA-led study concluded that organic molecules detected on Mars are difficult to explain through non-biological processes, bolstering the possibility of past or present life on the red planet. The analysis considered various non-biological origins, including interplanetary dust, meteorites, and atmospheric processes, but found these insufficient to account for the observed abundance of the molecules.
Further complicating the search for life beyond Earth, a new model suggests the Milky Way’s central supermassive black hole may instead be a dense concentration of fermionic dark matter. Astrophysicist Carlos Argüelles of the Institute of Astrophysics La Plata in Argentina explained that this model proposes the central object and the galaxy’s dark matter halo are manifestations of the same substance.
On the medical front, researchers are gaining a better understanding of the mechanisms behind memory loss in Alzheimer’s disease. A new study in mice suggests the disease disrupts the brain’s “replay mode,” a process crucial for consolidating memories. Neuroscientist Caswell Barry noted that while replay events still occur in the brains of affected mice, their structure is abnormal, indicating a failure in the memory consolidation process itself.
A separate study, published in April 2025, examined the relationship between excessive daytime sleepiness, long sleep duration, and the risk of all-cause dementia. The research, conducted by a team at the University of Newcastle and Pennsylvania State University, investigated these factors as potential indicators of cognitive decline.
Finally, a new experimental treatment for sleep apnea, involving a minimally invasive implantable electrode, has demonstrated a 93 percent success rate in human trials. Otolaryngologist Simon Carney of Flinders University described the procedure as a 90-minute process performed under ultrasound guidance, offering a potential solution for patients previously unsuitable for traditional surgery.
